Compound improves health, increases lifespan of obese mice

August 22, 2011 in Medical research

(Medical Xpress) -- Researchers have reported that obese male mice treated with a synthetic compound called SRT1720 were healthier and lived longer compared to non-treated obese mice. The experimental compound was found to improve the function of the liver, pancreas and heart in mice.

The National Institute on Aging (NIA) supported the study, in collaboration with Sirtris, a company. The study was primarily conducted by the NIA, part of the National Institutes of Health, and is published online in the Thursday, August 18, 2011, issue of Scientific Reports.

"This study has interesting implications for research on the biology of aging. It demonstrates that years of healthy life can be extended in an of diet-induced obesity by a that modulates a gene pathway associated with aging," said NIA Director Richard J. Hodes, M.D. More research is needed to assess the relevance of these findings in people, Hodes and the researchers noted.

SRT1720, a patented molecule, has been shown to activate the SIRT1enzyme, part of a class of enzymes called sirtuins. Sirtuins have been previously implicated in aging processes and are thought to contribute to the positive effects of (also known as ) in higher organisms, including nonhuman primates.

In this study, scientists compared the health of 1-year-old, or middle-aged, male mice fed a high-fat with a high dose of SRT1720, a low dose of SRT1720 or no SRT1720. Additionally, these mice were compared to a control group of 1-year-old male mice fed a standard diet.

"As we hypothesized, SRT1720 mimics dietary restriction, moderating many of the harmful effects of the high-fat diet and obesity. Furthermore, we found that the higher dose of the compound had a stronger effect and there were no signs of toxicity from SRT1720 even after 80 weeks of treatment," said study leader and senior author Rafael de Cabo, Ph.D., of the Laboratory of Experimental Gerontology at the NIA.

Scientists reported changes caused by SRT1720 in following areas:

• Lifespan. While all mice on the high-fat diet gained weight, mice treated with SRT1720 had an increased average and maximum lifespan compared to mice on the high-fat diet without SRT1720. From birth, the mice on the higher dose lived an average of 18 percent longer, and the mice on the lower dose lived an average of 4 percent longer than the mice on the high-fat diet without SRT1720. From 56 weeks of age, mean lifespan in low-dose mice increased by 11 percent and in high-dose mice by 44 percent.

• Liver. Mice treated with SRT1720 had less fat accumulation on their livers compared to non-treated, high-fat-diet mice. Scientists also tested liver function using two measurements. In both tests, mice treated with SRT1720 demonstrated better liver function than non-treated mice on a high-fat diet, but only one test showed the liver of treated mice to have equal function as mice on standard diet. Livers of treated mice were smaller than those from untreated mice on a high-fat diet, although they were still larger than livers of mice on a standard diet. In addition, SRT1720 suppressed liver inflammation and protected mice against cell death in the liver.

. SRT1720 protected high-fat-diet mice from resistance to insulin, which is often associated with obesity and can precede diabetes. Glucose (blood sugar) measurements were approximately equal for all groups of mice, including mice on a standard diet. Insulin levels were approximately double in mice on the high-fat diet without SRT1720 compared to mice on the standard diet and on a high-fat diet with SRT1720.

• Heart. High-density lipoprotein (HDL), associated with good cardiovascular health, was highest in mice on a high-fat diet with a high dose of SRT1720, even compared to mice on a standard diet. SRT1720 protected mice against cell death in the heart and suppressed inflammation. All groups of mice on a high-fat diet experienced the same increase in cholesterol, compared to mice on a standard diet.

• Exercise and oxygen metabolism. Mice on a high-fat diet had higher levels of oxygen consumption during periods typically characterized by less activity. SRT1720 reversed this trend; treated mice had lower resting levels of oxygen. High-fat-diet mice with no or a low dose of SRT1720 were less active than mice on a high dose of SRT1720 or on a standard diet.

• Genes. SRT1720 suppresses genes typically expressed in mice on a high-fat diet. For example, SRT1720 suppressed genes that are associated with aging in the liver and previously identified as associated with aging in the kidney and brain.

To verify that the positive health effects caused by SRT1720 were, at least in part, dependent on the Sirt1 pathway, scientists conducted a series of experiments using cell cultures. The researchers also assessed changes to mitochondrial respiration in adult Sirt1-specific knockout mice. The tests showed that SRT1720 did not have an effect in mice or cultures lacking the Sirt1 gene although it did have an effect in mice and cultures with Sirt1.

While the findings are promising, scientists emphasize the limitations of their research.

"In mice, SRT1720 reversed many of the health problems associated with a high-fat diet and did not have toxic side effects, but it is too early to know whether these findings could be replicated in other animal models, much less humans," said de Cabo. "The bottom line is that we need much more research before considering SRT1720 or related compounds as a possible treatment for diseases of aging."

The study is a collaborative effort between the laboratories of de Cabo; James L. Ellis of Sirtris, and David A. Sinclair, Ph.D., co-director of the Glenn Laboratories for Molecular Biology of Aging at Harvard Medical School, Boston and consultant to Sirtris. Researchers from the following institutions also collaborated in the study: University of Pennsylvania School of Medicine, Philadelphia; University of Oklahoma Health Sciences Center, Oklahoma City; Ècole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; University of Michigan, Ann Arbor; and University of Kentucky, Lexington.

This research was performed under a Cooperative Research and Development Agreement between the NIA and Sirtris, a GSK company.

Provided by National Institutes of Health

not rated yet  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

Vendicar_Decarian
Aug 22, 2011

Rank: 1 / 5 (2)
Another fine result brought to you by Government funding from the NIH.

Where would Sirtris be without the people's money?

Bankrupt? Nonexistent? Never having existed?

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria

In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...

Medical research created May 17, 2013 | popularity 3.7 / 5 (3) | comments 0 | with audio podcast

SUMO wrestling cells reveal new protective mechanism target for stroke

Scientists investigating the interaction of a group of proteins in the brain responsible for protecting nerve cells from damage have identified a new target that could increase cell survival.

Medical research created May 17, 2013 | popularity 5 / 5 (1) | comments 0

How serotonin receptors can shape drug effects, from LSD to migraine medication

New findings by researchers carrying out experiments at the U.S. Department of Energy Office of Science's Advanced Photon Source (APS) help explain why some drugs that interact with two kinds of human serotonin ...

Medical research created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast

Preventing blood poisoning

Peptide molecules derived from the body's natural immune system can help boost the body's defence against life-threatening blood poisoning, joint University research has uncovered.

Medical research created May 17, 2013 | popularity 4 / 5 (1) | comments 0 | with audio podcast

New mechanism to prevent type 2 diabetes in obese individuals

A new Montréal study conducted by Dr. May Faraj, associate research professor at the Université de Montréal and invited scientist at the IRCM, along with her research team and medical collaborators, shows ...

Medical research created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast


Ketamine shows significant therapeutic benefit in people with treatment-resistant depression

Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...

Consuming coffee linked to lower risk of detrimental liver disease, study finds

Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...

Research examines new methods for managing digestive health

Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.

New smartphone application improves colonoscopy preparation

The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...

New research identifies practice changes to improve value and quality of GI procedures

There are significant cost and risk factors associated with two procedures commonly used to diagnose or treat gastrointestinal problems, according to research presented at Digestive Disease Week (DDW).

New research identifies risks, interventions for children's GI health

An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).